Alcon, a global leader in eye care, has acquired BELKIN Vision for a total upfront consideration of $81 million. The deal also includes the potential for up to $385 million in payments based on sales-based milestones. The acquisition includes BELKIN Vision’s Direct Selective Laser Trabeculoplasty (DSLT) technology, expanding Alcon’s glaucoma portfolio with a first-line therapy. For glaucoma, Alcon also offers implantables such as Hydrus Microstent, and pharmaceutical drops that are currently available in the U.S. 

“As a therapy with significant advantages for the patient and practice, we believe our newly acquired DSLT technology is uniquely positioned to accelerate the evolution toward first-line use of SLT in the glaucoma treatment paradigm,” said Sean Clark, President, Global Surgical Franchise, Alcon. “We look forward to broadening access to this exciting technology in the future as we continue to address solutions for unmet needs in glaucoma.” 

“Despite ample evidence for SLT as primary therapy in glaucoma treatment, practical challenges limit availability to many patients who could benefit from it,” said Nathan M. Radcliffe, M.D. “DSLT will have a profound impact on laser-first, helping to overcome these barriers and meaningfully improve access to laser therapy—shifting doctor and patient perceptions around efficiency and comfort.” 

The DSLT technology is approved in the European Union and the United Kingdom, and is indicated to perform SLT. The device received 510(k) Clearance from the U.S. FDA but is not yet available in the U.S. With this acquisition, Alcon plans to continue to supply DSLT in the EU and UK, and aims to make the device available to physicians in the U.S. by the end of 2024.